PLUVICTO™ | Lutetium Lu 177 vipivotide tetraxetan
What is PLUVICTO ® (lutetium Lu 177 vipivotide tetraxetan)? PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant …
Lutetium (177Lu) vipivotide tetraxetan - Wikipedia
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
Lutetium Lu 177 Vipivotide Tetraxetan - NCI - National Cancer …
Lutetium Lu 177 vipivotide tetraxetan is approved to treat: Prostate cancer that overproduces the PSMA protein and did not respond to treatments that lower testosterone levels. It is used in adults whose cancer has spread to other parts of the body and has been treated with an androgen receptor blocker and taxane -based chemotherapy.
Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto)
Lutetium-177 vipivotide tetraxetan PSMA therapy (Pluvicto) is a new theranostic medicine for advanced metastatic prostate cancer. It’s a type of radiation that specifically targets a molecule on the surface of prostate cancer cells called PSMA.
Lutetium lu 177 vipivotide tetraxetan (intravenous route)
2024年1月31日 · Lutetium Lu 177 vipivotide tetraxetan injection is used to treat prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has spread to other parts of the body) in patients who have received other cancer ...
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval - PubMed
Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as 177 Lu-PSMA-617) is a radioligand therapeutic agent that is being developed by Advanced Accelerator Applications (a subsidiary of Novartis) for the treatment of prostate-specific membrane antigen (PSMA)-expressing metastat …
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval - PMC
Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as 177 Lu-PSMA-617) is a radioligand therapeutic agent that is being developed by Advanced Accelerator Applications (a subsidiary of Novartis) for the treatment of prostate-specific membrane antigen (PSMA)-expressing metastatic prostate cancer. The active part of the ...
Clinical Review - Lutetium (177Lu) Vipivotide Tetraxetan …
Lutetium-177 (177 Lu) vipivotide tetraxetan (Pluvicto) contains the radionuclide lutetium-177, which is linked to a targeting moiety that binds to PSMA. Upon the binding of 177 Lu vipivotide tetraxetan to PSMA-expressing cancer cells, the beta-minus emission from lutetium-177 delivers therapeutic radiation to the targeted cell, as well as to ...
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan …
2023年5月1日 · On March 23, 2022, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen r …
Treatment Center Locator I PLUVICTO
What is PLUVICTO ® (lutetium Lu 177 vipivotide tetraxetan)? PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant …